Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 169

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 169
---
 adversely affected in a material way. This could cause the market price of the combined company common stock to decline. The market price of the combined company common stock is expected to be volatile, and the market price of the common stock may drop following the Merger. The market price of the combined company common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company common stock to fluctuate include:

| • | the success of competitive products or announcements by potential competitors of their product development efforts; |

| • | failure to meet or exceed financial and development projections the combined company may provide to the public; |

| • | failure to meet or exceed the financial and development projections of the investment community; |

| • | if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; |

| • | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors; |

| • | actions taken by regulatory agencies with respect to the combined company’s product candidates, clinical studies, manufacturing process or sales and marketing terms; |

| • | disputes or other developments relating to proprietary rights, including patents, trade secrets, litigation matters, and the combined company’s ability to obtain patent protection for its technologies or maintain its trade secrets; |

| • | disputes or termination of agreements with third parties, including CMOs, supporting with the manufacturing and clinical studies of the combined company’s product candidates; |

| • | additions or departures of key personnel; |

| • | significant lawsuits, including patent or stockholder litigation; |

| • | if securities or industry analysts do not publish research or reports about the combined company’s business, or if they issue adverse or misleading opinions regarding its business and stock; |

| • | if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; |

| • | changes in the market valuations of similar companies; |

| • | geo-political developments, general market or macroeconomic conditions including inflation and interest rates; |

| • | market conditions in the pharmaceutical and biotechnology sectors; |

| • | expiration of market stand-off or lock-up agreements; |

| • | changes in the structure of healthcare payment systems; |

| • | announcement of expectation of additional financing efforts; |

| • | sales of securities by the combined company or its securityholders in the future